Cystatin C allows to detect early progression of chronic kidney disease in patients with acute decompensation of chronic heart failure
- Authors: Davydov V.V1, Arechina E.L2
-
Affiliations:
- Altai State Medical University of the Ministry of Health of the Russian Federation
- Сity Clinical Hospital №8
- Issue: Vol 20, No 12 (2018)
- Pages: 30-34
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95113
- DOI: https://doi.org/10.26442/20751753.2018.12.180155
- ID: 95113
Cite item
Full Text
Abstract
Objective - to compare the value of serum creatinine and cystatin dynamics for early diagnosis of chronic kidney disease progression in patients with acute decompensation of chronic heart failure. Materials and methods. The study included 125 patients with acute decompensation of chronic heart failure who received treatment in the therapy department. The dynamics of glomerular filtration rate was monitored by level of serum creatinine and cystatin C at the beginning and at the end of treatment. Results. Upon admission to the hospital, 14 cases of progression of chronic kidney disease in terms of creatinine and 39 in terms of cystatin C. The increase in creatinine levels was accompanied by an increase in cystatin C levels in 100% of cases. At the end of treatment, elevated cystatin C levels persisted in 34 patients. This was accompanied by an increase in creatinine levels in 100% of cases. There were identified 11 new cases of progression of chronic kidney disease; 6 cases on two indicators, 5 cases on one indicator. Conclusion. Evaluation of glomerular filtration rate by serum cystatin C level allowed to identify progression of chronic kidney disease at early stages in patients with acute decompensation of chronic heart failure 2.4 times more often than evaluation serum creatinine level
Full Text
##article.viewOnOriginalSite##About the authors
V. V Davydov
Altai State Medical University of the Ministry of Health of the Russian Federation
Email: 6davv@mail.ru
д-р мед. наук, проф. каф. анестезиологии, реаниматологии и клинической фармакологии с курсом ДПО 656038, Russian Federation, Barnaul, pr-t Lenina, d. 40
E. L Arechina
Сity Clinical Hospital №8
Email: arehina_katerina@mail.ru
зам. глав. врача 656010, Russian Federation, Barnaul, ul. Petra Sukhova, d. 13
References
- Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Сердечная недостаточность. 2017; 18 (1): 3-40.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Inter (Suppl.) 2013; 3: 1-150.
- Искендеров Б.Г. Кардиоренальный синдром у кардиологических больных. Монография. Пенза, 2014
- Ponikowski P, Voors A.A, Anker S.D et al. Рекомендации ESC по диагностике и лечению острой и хронической сердечной недостаточности. Рос. кардиол. журн. 2017; 1 (141): 7-81.
- Урясьев О.М., Дубинина И.И., Берстнева С.В. Исследование цистатина С при хронической болезни почек у больных сахарным диабетом 2 типа. Мед. вестн. Северного Кавказа. 2016; 11 (4): 537-9.
- Кузнецова Т.Е., Боровкова Н.Ю. Цистатин С в диагностике хронической болезни почек в клинической практике. Архивъ внутренней медицины. 2014; 6 (20): 38-41.
- Смирнов А.В., Добронравов В.А., Румянцев А.Ш. и др. Национальные рекомендации. Острое повреждение почек: основные принципы диагностики, профилактики и терапии. Ч. 1. Нефрология. 2016; 20 (1): 79-104.
